An observational study in Pituitary Tumor, sponsored by Hospices Civils de Lyon. Status unknown at 1 site in France. Per ClinicalTrials.gov, last updated 2016-08-03.
Sponsored by Hospices Civils de Lyon · Observational
The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity through computerized collection of comprehensive demographic, therapeutic, pathologic and outcome information on patients harboring pituitary mass lesions of all types.
180 studies on the registry are indexed under Pituitary Neoplasms; 48 are open to participants now.
This study's planned enrollment of 1,300 is above the median of 150 across 75 observational studies indexed under Pituitary Neoplasms.
Browse Pituitary Neoplasms studies →Hospices Civils de Lyon is the lead sponsor of 1,854 studies on the registry; 441 are open to participants now.
Counted across the registry records on this site, refreshed daily.
tertiary referral center
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Progression free survival after pituitary surgery according to the clinicopathological classification (HYPOPRONOS)
Clinical, biochemical et imaging evaluation of a cohort of patient operated in the referral center for pituitary tumor. Identification of recurrence or progression an analysis of the clinicopathological classification. Evaluation of the different therapeutic strategies (med, surgery, chemotherapies, radiation therapy) to prevent recurrence or tumor progression.
Time frame: up to 10 years (postoperatively)
Correlation between percentage of SSTR expression of the pituitary tumor and somatostatine analogs efficacy.
Analysis of the expression of SST receptors in GH, PRL and ACTH secreting pituitary tumors: SSTR expression accessed by immunohistochemistry of the pituitary tumor. Evaluation of the response to somatostatine analogs: somatostatine analogs efficacy evaluated by normalization of hormone hypersecretion in ACTH, GH and PRL secreting pituitary tumor.
Time frame: 2007-2020
Correlation between percentage of MGMT expression of the pituitary tumor and tumor response to temozolomide.
Evaluation of MGMT expression (accessed by immunohistochemistry of the pituitary tumor) and response to temozolomide treatment (evaluated according to RECIST criteria) for patient presenting multirecurrent tumors resistant to conventional treatment.
Time frame: 2007-2020
This study is status unknown, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.